Compare · CERS vs INFY
CERS vs INFY
Side-by-side comparison of Cerus Corporation (CERS) and Infosys Limited (INFY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and INFY operate in EDP Services (Technology), so they compete in similar markets.
- INFY is the larger of the two at $51.01B, about 97.9x CERS ($521.0M).
- Over the past year, CERS is up 73.3% and INFY is down 33.7% - CERS leads by 107.0 points.
- CERS has been more active in the news (12 items in the past 4 weeks vs 11 for INFY).
- INFY has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Infosys Limited
- Price
- $2.56-1.54%
- $12.13-1.34%
- Market cap
- $521.0M
- $51.01B
- 1M return
- -1.91%
- -5.57%
- 1Y return
- +73.31%
- -33.67%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 12
- 11
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Infosys Limited
Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally. It provides application development and management, independent validation, product engineering and management, infrastructure management, enterprise application management, and support and integration services. The company's products and platforms include Finacle, a core banking solution; Edge suite of products; Infosys Nia, an artificial intelligence platform; Infosys McCamish - an insurance platform; Wingspan, a customizable learning platform; Stater mortgage servicing platform; Panaya automation suite; and Skava, an e-commerce suite. The company serves clients in the financial services and insurance, life sciences and healthcare, manufacturing, retail, consumer packaged goods and logistics, hi-tech, communications, telecom OEM, media, energy, utilities, resources, services, and other industries. It has collaboration agreements with Rolls-Royce, BP plc, Newmont Corporation, RXR Realty, Majesco Limited, and Centre for Accessibility Australia. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Limited in June 2011. Infosys Limited was incorporated in 1981 and is headquartered in Bengaluru, India.
Latest CERS
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Cerus Corporation Closes New Debt Facility of Up to $110 Million
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Lucena Ann was granted 60,000 shares, increasing direct ownership by 35% to 232,284 units (SEC Form 4)
- Director Bjerkholt Eric was granted 60,000 shares, increasing direct ownership by 27% to 282,133 units (SEC Form 4)
- Director Nachtsheim Jami K was granted 60,000 shares, increasing direct ownership by 29% to 268,362 units (SEC Form 4)
- Chief Operating Officer Jayaraman Vivek K sold $50,001 worth of shares (16,667 units at $3.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1.00% to 1,656,707 units (SEC Form 4)
- Director Witney Frank was granted 60,000 shares, increasing direct ownership by 21% to 340,059 units (SEC Form 4)
- Director Gregory Dean A. was granted 60,000 shares, increasing direct ownership by 69% to 146,725 units (SEC Form 4)
- Director Shan Hua was granted 60,000 shares, increasing direct ownership by 45% to 192,386 units (SEC Form 4)
Latest INFY
- Infosys and LTA Launch AI-Driven Match and Fan Experiences at the HSBC Championships, and Beyond
- NICE Actimize X-Sight Enterprise Cloud Solutions Selected by DNB Norway to Transform its Fraud and Financial Crime Operations
- Infosys Expands Strategic Collaboration with DNB Bank ASA to Modernize Financial Crime Operations
- Infosys and Handelsblatt Media Group Unveil AI-Powered Editorial Engine to Enhance Storytelling and Enrich Reader Experience
- SEC Form 6-K filed by Infosys Limited
- SEC Form 6-K filed by Infosys Limited
- SEC Form 6-K filed by Infosys Limited
- Chief Financial Officer Sanghrajka Jayesh sold $5,665,250 worth of Indian Equity Shares (5,191 units at $1,091.36), decreasing direct ownership by 3% to 180,471 units (SEC Form 4)
- SEC Form 6-K filed by Infosys Limited
- Chief Human Resources Officer Mathew Shaji sold $807,606 worth of Indian Equity Shares (740 units at $1,091.36), decreasing direct ownership by 0.23% to 317,561 units (SEC Form 4)